Last updated: February 20, 2026
What does Patent CN105407896 Cover?
Patent CN105407896, filed by CStone Pharmaceuticals, pertains to a novel antibody-drug conjugate (ADC) targeting specific cancer-associated antigens. The patent claims focus on the structure of the ADC, its composition, and methods of use. The patent's scope primarily includes:
- A specific monoclonal antibody linked to a cytotoxic agent.
- The conjugation method involving a linker chemistry.
- Therapeutic methods for treating cancer using the ADC.
The patent claims are centered on the novel combination of components and their specific linkage chemistry, aiming to improve stability, targeting, and efficacy against tumors.
How Broad Are the Claims?
The patent claims fall into three categories:
- Composition claims: Covering the ADC with particular monoclonal antibody and linker-drug conjugates.
- Method claims: Encompassing methods of manufacturing and using the ADC for cancer therapy.
- Use claims: Covering specific indications, mainly targeting human cancers expressing certain antigens.
The composition claims are moderately broad, encompassing various variants of the linker and antibody. However, they specify a particular antibody sequence and linker chemistry, limiting the scope relative to more generic ADC patents.
Limitations and Specificity
- The claims specify the amino acid sequences of the antibody, restricting variants.
- The linker chemistry is defined and does not include all possible conjugation chemistries.
- The claims do not extend to other drug payloads beyond the specified cytotoxic agent.
Patent Claims Language
Examining the patent claims reveals precision, with a focus on the linkage site, antibody sequence, and conjugation method. For example:
"An antibody-drug conjugate comprising an antibody comprising the amino acid sequence of SEQ ID NO: 1 conjugated to a cytotoxic agent via a linkage selected from the group consisting of..."
This specificity indicates a narrower claim scope, reducing the risk of design-arounds but limiting broad coverage.
Patent Landscape and Prior Art Comparison
Existing ADC Patents in China
China's ADC patent landscape features a mix of broad composition claims and narrow method claims. Leading players, such as Zhangjiang Hi-Tech Park-based companies, hold patents targeting specific antibody sequences and linker chemistries.
Global Patent Context
Globally, ADC patents are highly active, with key patents from companies like Seattle Genetics (ADC patents with broad claims on linker-payload chemistry) and Roche. Patent CN105407896 aligns with a trend toward more specific, antibody and linker-designed therapies rather than broad-spectrum claims.
Notable Patent Families and Overlaps
- Similar patents exist with specific antibody sequences targeting HER2 and other tumor antigens.
- Some patents cover general conjugation techniques, while CN105407896 emphasizes specific linkage chemistry and antibody sequences.
The patent landscape suggests that CN105407896 complements existing patents, filling a niche with its particular antibody and conjugation method.
Implications for Commercialization and R&D
- Patent Strength: The specific claims limit legal challenges but restrict manufacturing freedom.
- Freedom-to-Operate (FTO): Likely narrow, due to the specificity of antibody sequence and chemistry. R&D teams should analyze related patents, especially from major pharma.
- Innovation Opportunities: Modifications to linker chemistry and antibody variants could bypass the patent.
Strategic Considerations for Stakeholders
- Manufacturers should assess the patent's claims against their ADC candidates.
- Companies developing similar ADCs must evaluate potential infringement risks.
- Licensing agreements could allow safe entry or extension of patent life.
Conclusions
Patent CN105407896 protects a specific ADC structure with defined antibody and linker chemistry. Its claims are moderately broad but limited by specificity, and the patent landscape in China is active but fragmented, with room for innovation and design-around strategies.
Key Takeaways
- The patent's scope centers on a specific antibody and linker chemistry.
- Its claims are narrow, reducing infringement risks but limiting broad coverage.
- The Chinese ADC patent landscape remains competitive, emphasizing targeted, specific innovations.
- Patent protection complements a global trend toward precise, tailored ADC therapies.
- Major players should analyze related patents for FTO and potential licensing.
Frequently Asked Questions
-
What is the primary focus of patent CN105407896?
It covers a specific antibody-drug conjugate with defined antibody and linker chemistry for cancer therapy.
-
How broad are the patent claims?
They are moderately broad but limited by specific antibody sequences and linker types.
-
Can other companies develop similar ADCs in China?
Yes, but modifications to antibody sequences or conjugation methods may avoid infringement.
-
How does this patent compare internationally?
It aligns with a global trend toward specific, targeted ADCs, with similar patents from major companies focusing on particular antibody and chemistry combinations.
-
What strategic steps should be taken considering this patent?
R&D teams should conduct detailed patent FTO analyses and consider design-arounds or licensing.
References
[1] China National Intellectual Property Administration. (2016). Patent CN105407896. Retrieved from the official patent database.
[2] WIPO. (2022). Patent Landscaping for Antibody-Drug Conjugates. World Intellectual Property Organization.
